Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 10,564 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: Prolapse, Vaginal, Prolapse, Uterine, Prolapse; Female
Interventions: Educational Video, Standard Counseling; Other
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Cystic Fibrosis
Interventions: Denufosol Tetrasodium (INS37217) Inhalation Solution, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 5 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 82
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 72 more

Conditions: Duchenne Muscular Dystrophy
Interventions: PF-06252616; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 18 Years · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 26
States / cities: Los Angeles, California • Sacramento, California • Iowa City, Iowa + 9 more

Conditions: Cytomegalovirus Prophylaxis
Interventions: Letermovir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: Up to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more

Conditions: Influenza Prevention
Interventions: INFLUENZA G1 mHA, Placebo, Al(OH)3; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Miami Lakes, Florida • Lenexa, Kansas • Metairie, Louisiana + 1 more

Conditions: Cardiac Arrest, Cardiopulmonary Arrest
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 0 Years to 18 Years
Enrollment: 7,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 42
States / cities: Los Angeles, California • Madera, California • Orange, California + 33 more

Conditions: Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
Interventions: Elimusertib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 30 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Hypertension
Interventions: irbesartan, placebo, PS433540; Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 40
States / cities: Pell City, Alabama • Tempe, Arizona • Tucson, Arizona + 36 more

Conditions: Dry Eye Disease
Interventions: NOV03, Saline Solution; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 35
States / cities: Phoenix, Arizona • Garden Grove, California • Hemet, California + 29 more

Conditions: Heart Failure, Heart Decompensation
Interventions: Cinaciguat (BAY58-2667), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Chicago, Illinois • Detroit, Michigan • Cincinnati, Ohio + 3 more

Conditions: Cervical Cancer
Interventions: cisplatin, gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 105
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more

Conditions: Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions: Barostim System, Usual care medical management; Device · Other
Lead sponsor: CVRx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 23
States / cities: Mobile, Alabama • Los Angeles, California • Clearwater, Florida + 18 more

Conditions: Relapsed Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Lymphoblastic Lymphoma
Interventions: Sirolimus; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 30 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Autism Spectrum Disorder, Autism, Developmental Delay, Autism, Early Infantile, Autism, Infantile
Interventions: Assessment by Expert Clinician During Behavioral Intervention (ABA or similar), Assessment by the EarliPoint Assessment For Autism Spectrum Disorder; Behavioral · Device
Lead sponsor: EarliTec Diagnostics, Inc; Industry
Eligibility: 15 Months to 84 Months
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 9
States / cities: Phoenix, Arizona • Glendale, California • San Rafael, California + 6 more

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 78
States / cities: Tuscaloosa, Alabama • Peoria, Arizona • Scottsdale, Arizona + 68 more

Conditions: Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
Interventions: Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy; Drug · Radiation · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2037
U.S. locations: 679
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more

Conditions: Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: Not listed
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 11
States / cities: Aurora, Colorado • Miami, Florida • Chicago, Illinois + 8 more

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more

Conditions: Migraine
Interventions: Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more

Conditions: Depressive Disorder, Major
Interventions: Rapastinel; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 74
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 67 more

Conditions: Anemia
Interventions: Methoxy Polyethylene Glycol-Epoetin Beta, Epoetin alfa, Epoetin beta, Darbepoetin alfa; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 83
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 69 more

Conditions: Lymphoma, Non-Hodgkin
Interventions: Ibrutinib, Rituximab, Ifosfamide, Carboplatin, Etoposide, Vincristine, Idarubicin, Dexamethasone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 1 Year to 30 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 17
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 14 more

Conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 44
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 38 more

Conditions: Crohn Disease
Interventions: Ozanimod, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 107
States / cities: Peoria, Arizona • North Little Rock, Arkansas • Camarillo, California + 84 more

Search by objective public record fields.

Impact of Preop Video on Patient Anxiety

Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease

An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults

Quality of Pediatric Resuscitation in a Multicenter Collaborative

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma

Treatment Monitoring in Autism Spectrum Disorder (ASD) in Children

A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease